Therapeutic potential of Kv3 channel modulators in preclinical models relevant to the pathophysiology of schizophrenia

We are thrilled to share a publication in the Journal of Psychopharmacology, led by Leger et al., that is the culmination of a long-standing collaboration between the University of Manchester and Autifony Therapeutics. The article demonstrates that AUT00206, a modulator of Kv3.1 and Kv3.2 channels, improved cognitive and social behaviour deficits in preclinical models relevant to the pathophysiology of schizophrenia.

These findings highlight an exciting new approach towards addressing critical unmet clinical needs in psychiatry.

Impacts of Kv3.1 Channels on Action Potentials in Fusiform Neurons From the Dorsal Cochlear Nucleus of Mice Before and After Hearing Onset

AUT00206, a novel and selective Kv3.1/3.2 channel modulator, restores cognitive dysfunction and negative symptoms in an animal model for schizophrenia symptomatology